We all tend to take our good health for granted until something happens which makes us realize how blessed we are to have it in the first place.
On 1st November 2018, the UK’s Home Secretary announced changes to the scheduling of cannabis under the Misuse of Drugs Act of 2001.
Following a consultation last year, the irrefutable support for medicinal cannabis expansion on the Isle of Man is spurring the government to improve access for patients on the island. We spoke to the Minister for Health and Social Care, David Ashford, about the issue.
As the UK Government tries desperately to salvage a shattered economy, an unlikely but profitable lifeline presents itself as the medical cannabis industry booms.
Medical cannabis, namely cannabis-based products for medicinal use in humans (CBPMs), has been moved from Schedule 1 to Schedule 2 under the Misuse of Drugs Regulation 20011 in November 2018 following a very effective publicity campaign about two children with severe epilepsy.
A number of mothers, each with a severely epileptic child, are today holding a vigil outside the offices of the Department of Health & Social Care, the London headquarters of NHSE, the Scottish Parliament, and the Welsh Assembly.
Louisiana House Approves Medical Marijuana For Any Debilitating Condition, Along With Delivery Services
The Louisiana House of Representatives overwhelmingly approved bills on Friday to significantly expand the state’s medical cannabis program by bringing in patients with more conditions and allowing dispensaries to deliver marijuana products directly to those patients’ homes.
Despite a 2018 schedule change allowing prescribing of medical cannabis, patients are still faced with multiple barriers, including misinformation, stigma, and financial constraints, preventing access to potentially life-changing medicine.
Patients have begun receiving medical cannabis through the post, as the coronavirus pandemic has left them unable to access the drug any other way.
Most Canadian pediatricians are shying away from medical cannabis for patients, knowing that it can hurt the developing brain and that there isn’t much research to guide them.